CDNA 8-K SEC Filing Analysis

Latest settled — T+20d

CDNA ▼ -8.07% at T+20d

LONG call ✗ call lost -8.07% · α vs SPY -13.89% · entry $22.42 → $20.61

Next anchor: T+60d in 4w

Currently $22.97 · +2.45% from $22.42 entry

Entry anchored
Apr 15, 04:39 PM ET
via Databento tick

T+1d

-4.46%

call -4.46% · α -5.67%

$21.42

settled 8w ago

T+5d

-10.53%

call -10.53% · α -11.51%

$20.06

settled 7w ago

T+20d

-8.07%

call -8.07% · α -13.89%

$20.61

settled 4w ago

T+60d

—

call — · α —

—

in 4w

Price Chart

Loading chart...

Executive Summary

CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focus on core testing services, while reporting preliminary Q1 2026 revenue of $118 million with 48% year-over-year growth in testing services revenue. The transaction includes a 6-month transition services agreement and a distribution agreement for North America.

Key Financial Metrics

Deal Value

$170.0M

Actionable Insight

The divestiture allows CareDx to focus on its core testing services business while receiving $170 million in cash. The strong 48% year-over-year growth in testing services revenue suggests the core business is performing well. The distribution agreement with Eurobio provides ongoing revenue from the divested products.

Key Facts

Divesting lab products business to Eurobio Scientific for $170 million in cash
Preliminary Q1 2026 revenue of $118 million, up 39% year-over-year
Testing services revenue of $91 million, up 48% year-over-year
Testing volume of 54,900, up 17% year-over-year
Transition services agreement for at least 6 months at Eurobio's expense
Eurobio grants CareDx exclusive distribution rights for post-transplant monitoring tests in North America

Financial Impact

$170 million cash proceeds from divestiture, $118 million in Q1 revenue

revenuedilutiondebt

Risk Factors

Execution risk in transitioning the divested business
Potential disruption to operations during the 6-month transition period
Dependence on Eurobio for future supply of divested products

Market Snapshot

Exchange

Nasdaq

Sector

Services-Medical Laboratories

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-043970
Document: tm2611749d1_8k.htm	0001104659-26-043970
Document: tm2611749d1_ex99-1.htm	0001104659-26-043970
Document: 0001104659-26-043970-index-headers.html	0001104659-26-043970
Document: 0001104659-26-043970-index.html	0001104659-26-043970
Document: 0001104659-26-043970.txt	0001104659-26-043970
8-K Data (Synthetic)	0001104659-26-043970

5 reports for CDNA

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CDNA — sortable, filterable
	Type				Now
Jun 5, 2026 7d ago	DEFA14A NEUTRAL ★ 2/10	$23.16 awaiting T+20	awaiting T+20	—	$22.97 (−0.82%)
Apr 28, 2026 6w ago	S-3ASR NEUTRAL ★ 5/10	$20.80 $22.16	▲ +6.54%	▲ +1.08%	$22.97 (+10.43%)
Apr 16, 2026 8w ago	8-K BULLISH ★ 8/10	$22.42 $20.61	▼ −8.07%	▼ −13.89%	$22.97 (+2.45%)
Feb 25, 2026 15w ago	8-K/A BULLISH ★ 8/10	$18.46 $18.08	▼ −2.06%	▲ +3.18%	$22.97 (+24.43%)
Feb 24, 2026 15w ago	8-K BULLISH ★ 7/10	$18.46 $18.08	▼ −2.06%	▲ +3.18%	$22.97 (+24.43%)

US Market Status

Market Closed — Opens Mon (48h 51m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access